TNDM · Tandem Diabetes Care Inc
$17.92
-1.67 (-8.52%)
At close · Aug 6
Earnings today
Market Cap
$1.34B
Shares
68.53M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$19.59
Open$19.25
Day$19.00–19.86
52W$9.98–29.65
Avg vol 30d1.9M
Short int13.1M · 19.1% float · 8.7d
Short vol63%
Last earningsAug 6, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 6
Up next
Earnings call today
Aug 6, 2026
Today
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.60
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+3%
above
Price vs 50-day avg
+17%
above
RSI (14)
65
neutral
MACD trend
Positive
52-week position
49%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+29%
trailing
6-month return
0%
trailing
YTD return
−11%
this year
Relative strength
−12%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $17 › 200d $19 — 200d above 50d
Institutional flow
Accumulating
89 of 275 funds reported for Jun 30 · net +1.0M sh shares · +14 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
19.14% of float · ▲ +3.0% MoM · 8.7 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
275 holders — mid 3-yr range
Squeeze score
87
high risk · 0–100
Fundamentals
Revenue growth
+8%
Y/Y
Gross margin
54%
expanding
EPS growth
−107%
Y/Y
Free cash flow
$-29.7M
Balance sheet
$260.1M
net debt
Quant / Vol
risk profile
Volatility
80%
annualized · 1-yr
Max drawdown
−55%
past year
ATR
5.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
Sales
· year ending December 31, 2026
Maintained
$1.07B – $1.09B
prior FY $1.01B
midpoint +5.9% Y/Y
U.S. sales
· year ending December 31, 2026
Initiated
$730M – $745M
Gross margin
· year ending December 31, 2026
Maintained
56% – 57%
Adjusted EBITDA margin
· year ending December 31, 2026
Non-GAAP
Initiated
5% – 6%
International sales
· year ending December 31, 2026
Maintained
$335M – $340M
Non-cash, stock-based compensation expense
· year ending December 31, 2026
Lowered
$65M
Non-cash charges included in cost of goods sold and operating ex
· year ending December 31, 2026
Lowered
$85M
Depreciation and amortization expense
· year ending December 31, 2026
Maintained
$20M
Guided vs delivered
· last 1 settled
Worldwide sales
2025 full year
guided $1B
$1.01B
Beat +1.5%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+3%
Bullish
Price vs 50-day avg
+17%
Bullish
RSI (14)
65
Neutral
MACD trend
Positive
Bullish
52-week position
49%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $17 › 200d $19 — 200d above 50d
Institutional flow
Accumulating
89 of 275 funds reported for Jun 30 · net +1.0M sh shares · +14 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
19.14% of float · ▲ +3.0% MoM · 8.7 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
275 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $10
Now $20 · 49%
52-wk high $30
vs 200-day avg +3%
vs 50-day avg +17%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $6.4M | Second Quarter 2026 | — |
|
|
|||
| Gross margin | 57% | Second Quarter 2026 | — |
| International shipments | 11,000 | Second Quarter 2026 | — |
| Pump shipments | 33,000 | Second Quarter 2026 | — |
| Shipments in the U.S. | 22,000 | Second Quarter 2026 | — |
| U.S. sales through the pharmacy channel | 10% | Second Quarter 2026 | — |
| International pump shipments | 10,000 | first quarter 2026 | — |
| United States pump shipments | 19,000 | first quarter 2026 | — |
|
|
|||
| Worldwide pump shipments | 29,000 | first quarter 2026 | — |
|
|
|||
| Free cash flow non-GAAP | $3.1M | Fourth Quarter 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TNDM
this stock
Tandem Diabetes Care Inc
|
$1.34B | -10.9% | +7.9% | — | 19.1% |
|
ABT
Abbott Laboratories
|
$186.86B | -14.1% | +5.7% | 30.1 | 1.4% |
|
SYK
Stryker Corp
|
$129.28B | -3.6% | +11.2% | 34.9 | 1.8% |
|
MDT
Medtronic plc
|
$110.07B | -8.9% | +8.4% | 23.1 | 1.5% |
|
BSX
Boston Scientific Corp
|
$71.45B | -49.9% | +5.5% | 20.0 | 2.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TNDM | +5.4% | +29.2% | -0.4% | +0.5% | -10.9% |
| SPY | +5.5% | +3.3% | +11.3% | +3.1% | +12.9% |
| vs SPY | -0.2% | +26.0% | -11.6% | -2.6% | -23.8% |
Key facts
CIK
1438133
CUSIP
875372203
13F (30d)
73 filings
73 filers
Visit website
Investor relations